Serge E. Przedborski
#110,519
Most Influential Person Now
Serge E. Przedborski's AcademicInfluence.com Rankings
Serge E. Przedborskibiology Degrees
Biology
#6079
World Rank
#8713
Historical Rank
Neuroscience
#718
World Rank
#750
Historical Rank

Download Badge
Biology
Serge E. Przedborski's Degrees
- Doctorate Medicine University of Buenos Aires
- PhD Neuroscience University of Buenos Aires
Why Is Serge E. Przedborski Influential?
(Suggest an Edit or Addition)Serge E. Przedborski's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Parkinson's Disease Mechanisms and Models (2003) (4794)
- PINK1-dependent recruitment of Parkin to mitochondria in mitophagy (2009) (1449)
- Oxidative Stress in Parkinson's Disease (2008) (1202)
- Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease (2002) (1189)
- Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons (2007) (1147)
- Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice (2002) (1096)
- Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease (1999) (1018)
- Protocol for the MPTP mouse model of Parkinson's disease (2007) (807)
- Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. (2000) (713)
- Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration (2003) (626)
- NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease (2003) (613)
- Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. (1996) (610)
- Toxin-induced models of Parkinson’s disease (2005) (606)
- Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. (2008) (570)
- Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. (1995) (559)
- Neurological diseases: Targeting programmed cell death in neurodegenerative diseases (2003) (539)
- Mitochondria: The Next (Neurode)Generation (2011) (514)
- Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy (2017) (502)
- Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. (1997) (501)
- The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety (2001) (485)
- Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP (2002) (478)
- Classic and New Animal Models of Parkinson's Disease (2012) (470)
- DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase (2007) (470)
- Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease (2009) (466)
- Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity (1992) (464)
- Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease (2012) (461)
- The Metabolic Topography of Parkinsonism (1994) (428)
- Motor blocks in Parkinson's disease (1992) (417)
- JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. (2004) (405)
- VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. (1997) (403)
- Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson's Disease (2010) (403)
- Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (1998) (397)
- D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. (2003) (396)
- α-Synuclein Is Localized to Mitochondria-Associated ER Membranes (2014) (394)
- α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP (2000) (390)
- Parkinson’s disease: animal models and dopaminergic cell vulnerability (2014) (387)
- Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. (1999) (368)
- Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease (2001) (358)
- Necroptosis Drives Motor Neuron Death in Models of Both Sporadic and Familial ALS (2014) (349)
- Neurodegeneration: what is it and where are we? (2003) (348)
- Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations (2015) (331)
- Freezing of gait in PD (2001) (328)
- The role of glial cells in Parkinson's disease (2001) (326)
- Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. (2004) (316)
- The kinase domain of mitochondrial PINK1 faces the cytoplasm (2008) (314)
- Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons (2008) (314)
- Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. (2006) (313)
- Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS (2002) (308)
- Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease (2003) (300)
- Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. (2005) (300)
- Increased expression of the pro‐inflammatory enzyme cyclooxygenase‐2 in amyotrophic lateral sclerosis (2001) (290)
- Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease (1991) (287)
- Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease (2003) (286)
- CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism (2005) (285)
- MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease (2004) (280)
- Pathogenic role of glial cells in Parkinson's disease (2003) (277)
- Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease (1995) (274)
- Lack of Nigral Pathology in Transgenic Mice Expressing Human α-Synuclein Driven by the Tyrosine Hydroxylase Promoter (2001) (272)
- Genetic clues to the pathogenesis of Parkinson's disease (2004) (265)
- The 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Mouse Model (2003) (264)
- Recruitment of the Mitochondrial-Dependent Apoptotic Pathway in Amyotrophic Lateral Sclerosis (2001) (259)
- The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice (2006) (255)
- Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* (1999) (252)
- Similar Patterns of Mitochondrial Vulnerability and Rescue Induced by Genetic Modification of α-Synuclein, Parkin, and DJ-1 in Caenorhabditis elegans* (2005) (252)
- Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice (2005) (249)
- The parkinsonian toxin MPTP: action and mechanism. (2000) (244)
- The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. (1989) (239)
- The two-century journey of Parkinson disease research (2017) (238)
- Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease (2007) (223)
- Neurodegeneration and inflammation in Parkinson's disease. (2012) (219)
- Inducible Nitric Oxide Synthase Up‐Regulation in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis (1999) (218)
- Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. (2001) (214)
- Freezing of gait in PD: Prospective assessment in the DATATOP cohort (2001) (211)
- Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. (2005) (207)
- Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson’s Disease (2009) (202)
- Enriched Environment Confers Resistance to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine and Cocaine: Involvement of Dopamine Transporter and Trophic Factors (2003) (201)
- Mechanisms of MPTP toxicity. (1998) (201)
- The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway (2009) (191)
- Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease (2001) (188)
- COX‐2 and Neurodegeneration in Parkinson's Disease (2003) (187)
- Pathogenesis of nigral cell death in Parkinson's disease. (2005) (183)
- COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital (2021) (182)
- Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice (2008) (181)
- Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes. (2013) (180)
- Clinical presentation and pharmacological therapy in corticobasal degeneration. (1998) (174)
- Nitric Oxide and Reactive Oxygen Species in Parkinson's Disease (2003) (170)
- Early differential diagnosis of Parkinson's disease with 18F‐fluorodeoxyglucose and positron emission tomography (1995) (169)
- Pathogenesis of Parkinson's disease (2013) (168)
- Neuroinflammation in glaucoma: A new opportunity (2017) (167)
- Bax and Bcl‐2 Interaction in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis (1999) (167)
- The metabolic topography of idiopathic torsion dystonia. (1995) (167)
- Programmed cell death in amyotrophic lateral sclerosis. (2003) (165)
- Selectively enhanced contextual fear conditioning in mice lacking the transcriptional regulator CCAAT/enhancer binding protein delta. (1998) (164)
- Delaying Caspase Activation by Bcl-2: A Clue to Disease Retardation in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (2000) (164)
- A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy (2000) (161)
- Metabolic correlates of levodopa response in Parkinson’s disease (2001) (160)
- A tale on animal models of Parkinson's disease (2011) (158)
- The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. (2003) (157)
- Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis (2013) (155)
- α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration (2006) (155)
- Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity (1993) (154)
- Mitophagy: the latest problem for Parkinson's disease. (2011) (152)
- MPTP: a review of its mechanisms of neurotoxicity (2001) (151)
- D2-Like Dopamine Autoreceptor Activation Reduces Quantal Size in PC12 Cells (1998) (150)
- Nitration and Inactivation of Tyrosine Hydroxylase by Peroxynitrite* (2001) (147)
- Developmental cell death in dopaminergic neurons of the substantia nigra of mice (2000) (146)
- Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats (1991) (145)
- Mitochondrial autophagy in cells with mtDNA mutations results from synergistic loss of transmembrane potential and mTORC1 inhibition. (2012) (145)
- Proteasome inhibition and Parkinson's disease modeling (2006) (143)
- Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease (1993) (141)
- Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients (2002) (137)
- Differences in Nigral Neuron Number and Sensitivity to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 Mice (1994) (136)
- Sonic Hedgehog Maintains Cellular and Neurochemical Homeostasis in the Adult Nigrostriatal Circuit (2012) (128)
- Inflammation in ALS and SMA: Sorting out the good from the evil (2010) (126)
- Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research (2012) (126)
- Mitochondrial Dynamics and Bioenergetic Dysfunction Is Associated with Synaptic Alterations in Mutant SOD1 Motor Neurons (2012) (125)
- A Computational Model of Motor Neuron Degeneration (2014) (120)
- Regulation of Dopaminergic Loss by Fas in a 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease (2004) (119)
- The rotenone model of Parkinson's disease (2003) (115)
- Cytosolic cleaved PINK1 represses Parkin translocation to mitochondria and mitophagy (2014) (106)
- Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats (1993) (103)
- Superoxide Dismutase, Catalase, and Glutathione Peroxidase Activities in Copper/Zinc‐Superoxide Dismutase Transgenic Mice (1992) (103)
- Multimodal Actions of Neural Stem Cells in a Mouse Model of ALS: A Meta-Analysis (2012) (102)
- Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis (1996) (101)
- Gene dosage and pathogenesis of Parkinson's disease. (2005) (99)
- Identification of Neurodegenerative Factors Using Translatome-Regulatory Network Analysis (2015) (98)
- Mitophagy and Parkinson's disease: Be eaten to stay healthy (2013) (94)
- Instrumental Activation of Bid by Caspase-1 in a Transgenic Mouse Model of ALS (2002) (94)
- Animal models of Parkinson's disease. (2012) (93)
- Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. (1999) (92)
- α‐Synuclein expression in substantia nigra and cortex in Parkinson's disease (1999) (87)
- Pink1 Kinase and Its Membrane Potential (Δψ)-dependent Cleavage Product Both Localize to Outer Mitochondrial Membrane by Unique Targeting Mode* (2012) (86)
- Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases (2006) (86)
- Fractalkine: moving from chemotaxis to neuroprotection (2006) (84)
- Inflammation and Parkinson's disease pathogenesis (2010) (83)
- Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis (1997) (83)
- α-Synuclein-Independent Histopathological and Motor Deficits in Mice Lacking the Endolysosomal Parkinsonism Protein Atp13a2 (2015) (80)
- Positron emission tomography-guided stereotactic brain biopsy. (1992) (78)
- Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas. (2019) (75)
- D-β-Hydroxybutyrate Is Protective in Mouse Models of Huntington's Disease (2011) (74)
- Sequential activation of individual caspases, and of alterations in Bcl‐2 proapoptotic signals in a mouse model of Huntington's disease (2003) (70)
- Effects of Wild‐Type and Mutated Copper/Zinc Superoxide Dismutase on Neuronal Survival and l‐DOPA‐Induced Toxicity in Postnatal Midbrain Culture (1997) (70)
- The role of nitric oxide in Parkinson's disease. (2001) (67)
- Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia (2005) (66)
- Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease (2011) (66)
- Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen (1991) (66)
- Effect of Unilateral Perinatal Hypoxic‐Ischemic Brain Injury in the Rat on Dopamine D1 and D2 Receptors and Uptake Sites: A Quantitative Autoradiographic Study (1991) (65)
- A new role for α‐synuclein in Parkinson's disease: Alteration of ER–mitochondrial communication (2015) (62)
- Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. (2009) (61)
- Programmed Cell Death in Amyotrophic Lateral Sclerosis: a Mechanism of Pathogenic and Therapeutic Importance (2004) (60)
- Blood superoxide dismutase, catalase and glutathione peroxidase activities in familial and sporadic amyotrophic lateral sclerosis. (1996) (59)
- Preparing a neurology department for SARS-CoV-2 (COVID-19) (2020) (59)
- Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death (2001) (58)
- The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications (2002) (58)
- Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults (2016) (57)
- Neuroleptics Up‐Regulate Adenosine A2a Receptors in Rat Striatum: Implications for the Mechanism and the Treatment of Tardive Dyskinesia (1995) (57)
- Metabolism of 3-Nitrotyrosine Induces Apoptotic Death in Dopaminergic Cells (2006) (56)
- Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans (1995) (55)
- Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. (1999) (54)
- PINK1/Parkin direct mitochondria to autophagy (2010) (54)
- Neuroinflammation and Parkinson's disease. (2007) (53)
- Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons (2018) (52)
- Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein to nuclear Cajal bodies. (2012) (51)
- Experimental developments in movement disorders: update on proposed free radical mechanisms. (1998) (49)
- Apoptosis‐inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins (2010) (49)
- Increased Superoxide Dismutase Activity Improves Survival of Cultured Postnatal Midbrain Neurons (1996) (48)
- L‐3‐hydroxyacyl‐CoA dehydrogenase II protects in a model of Parkinson's disease (2004) (48)
- Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6‐hydroxydopamine (2001) (47)
- Novel subcellular localization for α-synuclein: possible functional consequences (2015) (47)
- The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study (2021) (45)
- What can pluripotent stem cells teach us about neurodegenerative diseases? (2010) (45)
- The Role of the Innate Immune System in ALS (2012) (45)
- Positron emission tomographic findings in Filipino X‐linked dystonia–parkinsonism (1993) (44)
- Hemiparkinsonism‐hemiatrophy syndrome (1990) (42)
- Amelioration of the nigrostriatal pathway facilitated by ultrasound-mediated neurotrophic delivery in early Parkinson's disease. (2019) (41)
- Antiparkinsonian therapies and brain mitochondrial complex I activity (1995) (41)
- Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence (1991) (40)
- Sleep EEG in depressed and nondepressed patients with Parkinson's disease. (1991) (39)
- The Ubiquitination of PINK1 Is Restricted to Its Mature 52-kDa Form (2017) (39)
- The Regulatory Machinery of Neurodegeneration in In Vitro Models of Amyotrophic Lateral Sclerosis. (2015) (38)
- Randomized controlled phase II trial of glatiramer acetate in ALS (2006) (38)
- Free radical and nitric oxide toxicity in Parkinson's disease. (2003) (38)
- Nigrostriatal dopaminergic function in familial amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations (1996) (37)
- Positron emission tomography and histopathology in Creutzfeldt‐Jakob disease (1993) (34)
- Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. (1991) (33)
- Bilateral modulation of [3H]neurotensin binding by unilateral intrastriatal 6-hydroxydopamine injections: evidence from a receptor autoradiographic study (1991) (32)
- Metabolic topography of the hemiparkinsonism‐hemiatrophy syndrome (1994) (32)
- PINK1 Content in Mitochondria is Regulated by ER-Associated Degradation (2019) (31)
- Theophylline increases “on” time in advanced parkinsonian patients (1999) (31)
- Neuroleptic medications inhibit complex I of the electron transport chain (1994) (31)
- Reproducibility of monoamine metabolite measurements in human cerebrospinal fluid (1990) (31)
- Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis (2021) (29)
- Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson’s disease mouse model (2015) (28)
- Glial cell response: A pathogenic factor in Parkinson’s disease (2002) (27)
- A motif within the armadillo repeat of Parkinson’s-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway (2018) (27)
- Deletion of Ripk3 Prevents Motor Neuron Death In Vitro but not In Vivo (2019) (26)
- The Postnatal Development of AMPA Receptor Subunits in the Basal Ganglia of the Rat (1998) (26)
- Time course of the neuroprotective effect of transplantation on quinolinic acid-induced lesions of the striatum (1995) (26)
- Effect of unilateral perinatal hypoxic-ischemic brain injury on striatal dopamine uptake sites and D1 and D2 receptors in adult rats (1991) (26)
- Intrabody and Parkinson's disease. (2009) (25)
- Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. (1994) (24)
- Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment. (1998) (24)
- Trichothiodystrophy, mental retardation, short stature, ataxia, and gonadal dysfunction in three Moroccan siblings. (1990) (23)
- PINK1 points Parkin to mitochondria (2010) (22)
- PARKINSON'S DISEASE: molecular and therapeutic insights from model systems (2017) (22)
- The last decade in Parkinson's disease research. Basic sciences. (2001) (22)
- Autoradiography of dopamine receptors and dopamine uptake sites in the spontaneously hypertensive rat (1990) (21)
- Control of mitochondrial integrity in Parkinson's disease. (2010) (21)
- A Sequel to the Tale of p25/Cdk5 in Neurodegeneration (2008) (21)
- Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. III. Inactivation of CCK-8 by a phosphoramidon-sensitive endopeptidase (1984) (21)
- Recent advances in amyotrophic lateral sclerosis research (2003) (21)
- The effect of acute hemiplegia on intercostal muscle activity (1988) (20)
- Isolated palsy of the superior branch of the oculomotor nerve due to chronic erosive sphenoid sinusitis. (1993) (19)
- Erratum to “Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS” [Mol. Cell. Neurosci. 20 (2002) 553–562] (2003) (19)
- Systematic elucidation of neuron-astrocyte interaction in models of amyotrophic lateral sclerosis using multi-modal integrated bioinformatics workflow (2020) (19)
- A Computational Model of Motor Neuron Degeneration (2014) (18)
- Recent Advances in the Development of Stem‐Cell‐Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease (2021) (18)
- Randomized control trials in ALS: lessons learned (2004) (18)
- Development of human neural transplantation. (1992) (17)
- Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism‐hemiatrophy syndrome (1993) (17)
- Peroxiredoxin-2 links Cdk5 to neurodegeneration (2007) (16)
- Mitophagy in cells with mtDNA mutations (2012) (16)
- Glutamate pathway implication in amyotrophic lateral sclerosis: what is the signal in the noise? (2010) (15)
- Fentanyl‐induced dyskinesias (1995) (15)
- Slow increase of homovanillic acid in cerebrospinal fluid after levodopa administration (1996) (15)
- Role for VGLUT 2 in selective vulnerability of midbrain dopamine neurons (2019) (14)
- The MPTP Model of Parkinson’s Disease (2007) (14)
- Partial attenuation of chronic fluphenazine-induced changes in regional monoamine metabolism by D-α-tocopherol in rat brain (1991) (14)
- Is prostaglandin E2 a pathogenic factor in amyotrophic lateral sclerosis? (2006) (14)
- Effect of Unilateral Perinatal Hypoxic‐Ischemic Brain Injury in the Rat on Striatal Muscarinic Cholinergic Receptors and High‐Affinity Choline Uptake Sites: A Quantitative Autoradiographic Study (1991) (14)
- Engineered modeling and the secrets of Parkinson's disease (2001) (14)
- SARS-CoV-2 Infection Causes Dopaminergic Neuron Senescence (2021) (14)
- 5th International Symposium on Focused Ultrasound (2016) (13)
- Loss of ROS—a radical response (1998) (13)
- Positron emission tomography in hemiparkinsonism-hemiatrophy syndrome. (1993) (13)
- Discussion of Research Priorities for Gait Disorders in Parkinson's Disease (2021) (12)
- Induction of mania by apomorphine in a depressed Parkinsonian patient (1992) (12)
- Resistance of SOD-Transgenic Mice to Oxidative Stress (1992) (11)
- Axonal Degeneration: RIPK1 Multitasking in ALS (2016) (11)
- Lack of efficacy of phenytoin in the syndrome of inappropriate anti-diuretic hormone secretion of neurological origin. (1989) (11)
- Is there a pathogenic role for mitochondria in Parkinson's disease? (2009) (10)
- Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis (2007) (10)
- Decrease of vasoactive intestinal peptide, methionine-enkephalin, substance P and increase of neuropeptide Y immunoreactive nerve fibres in aganglionic colon of Hirschsprung's disease (1989) (10)
- Inflammatory demyelinating polyradiculoneuropathy associated with human immunodeficiency virus infection (1988) (10)
- Neurotensin high affinity binding sites and endopeptidase 24.11 are present respectively in the meningothelial and in the fibroblastic components of human meningiomas (1990) (10)
- Quantitative autoradiographic distribution of [3H]mazindol-labeled dopamine uptake sites in the brains of superoxide dismutase transgenic mice (1990) (10)
- Nervous system manifestations and neuroradiologic findings in acquired immunodeficiency syndrome (AIDS) (2004) (9)
- Neurodegenerative Diseases: Toxic animal models (2005) (9)
- Engineered modeling and the secrets of Parkinson's disease (2001) (9)
- Is prostaglandin E(2) a pathogenic factor in amyotrophic lateral sclerosis? (2006) (9)
- Quantitative autoradiographic distribution of [3H]-MPTP binding in the brains of superoxide dismutase transgenic mice (1991) (9)
- Lack of changes in ventricular cerebrospinal fluid concentrations of homovanillic acid following acute challenge with levodopa (1992) (9)
- Targeting α -synuclein for treating Parkinson’s disease: mechanistic and therapeutic considerations (2017) (9)
- Is Amyotrophic Lateral Sclerosis a Mitochondrial Channelopathy? (2010) (8)
- Cholecystokinin distribution in the human striatum and related subcortical structures (1989) (8)
- Neurotensin receptors in human meningiomas (1991) (7)
- Focused-ultrasound Mediated Anti-Alpha-Synuclein Antibody Delivery for the Treatment of Parkinson's Disease (2017) (6)
- COVID-19 manifestations in people with Parkinson’s disease: a USA cohort (2021) (6)
- Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease (2021) (6)
- Pink1 and its Δψ -dependent cleavage product both localize to the outer mitochondrial membrane by a unique targeting mode* (2012) (6)
- Autoradiographic evidence of [3H]neurotensin binding changes in discrete regions of brain in the rat model of persistent spasmodic dyskinesia induced by iminodipropionitrile (1989) (6)
- Variations of homovanillic acid levels in ventricular cerebrospinal fluid (1992) (6)
- Systemic and intrastriatal theophylline have opposite effects on dopamine and dopamine metabolites measured by intrastriatal microdialysis in the rat (1996) (6)
- Molecular targets for neuroprotection (2004) (6)
- From Man to Mouse: The MPTP Model of Parkinson Disease (2015) (6)
- Delayed-onset dyskinesias (1996) (5)
- | Amyotrophic Lateral Sclerosis | Taylor & Francis Group (2005) (5)
- Regional changes in brain 5-HT1A serotonin receptors in the rat model of persistent spasmodic dyskinesias induced by iminodipropionitrile (1989) (5)
- Sumoylation regulates the assembly and activity of the SMN complex (2021) (5)
- The MPTP Mouse Model of Parkinson's Disease: the True, the False, and the Unknown (2008) (5)
- When Schwann Cells Conspire with Mitochondria, Neighboring Axons Are under Attack by Glia-Derived Neurotoxic Lipids (2013) (4)
- Role of Nitric Oxide in MPTP Induced Dopaminergic Neuron (2000) (4)
- Quantitative autoradiographic changes in 5-[3H]HT-labeled 5-HT1 serotonin receptors in discrete regions of brain in the rat model of persistent dyskinesias induced by iminodipropionitrile (IDPN) (1990) (3)
- Does increased superoxide dismutase activity really cause muscular dystrophy? (1999) (3)
- Clarification: Pathogenic role of glial cells in Parkinson's disease (2004) (3)
- Mitochondrial dysfunction and neurodegenerative disorders (2006) (3)
- Neuropeptide Y, somatostatin, and cholecystokinin neurone preservation in anaplastic astrocytomas (2004) (3)
- Pathogenic Lrrk 2 substitutions and Amyotrophic lateral sclerosis (2007) (3)
- Transgenic superoxide dismutase overproducer: murine. (2002) (2)
- Advances in our Knowledge of MPTP Action and Mechanism (2000) (2)
- Effect of HECNU in malignant supratentorial gliomas — a phase II study (1988) (2)
- Motoneuron Diseases. (2022) (1)
- Therapeutic immunization protections dopaminergic neurons in a mouse model of Parkison's disease (2004) (1)
- Lipid level alteration in human and cellular models of alpha synuclein mutations (2022) (1)
- MPTP and Oxidative Stress: It’s Complicated! (2011) (1)
- Parkinson's disease : a subject collection from Cold Spring Harbor perspectives in meicine (2012) (1)
- A case of late onset striatonigral degeneration. (1989) (1)
- Neuroprotection and neuroregeneration triggered through the FUS-induced opening of the blood-brain barrier in a Parkinson’s mouse model (2015) (1)
- Retromer dysfunction in amyotrophic lateral sclerosis (2022) (1)
- Can we reverse alpha‐synuclein lesions? (2011) (1)
- Visualization of neuropeptides and neurotransmitters in the human brain. Applications to development and pathology.: Werner Gren International Symposium Series 45, pp 31-40 (1988) (1)
- [Current therapeutic approach in Parkinson disease]. (1992) (1)
- 3.14.1 MICROGLIA AND NEUROINFLAMMATION IN PD (2012) (1)
- Chapter 14 Cell Death Pathways in Amyotrophic Lateral Sclerosis (2003) (0)
- TITLE : Interaction of Synuclein and inflammation in Dopaminergic Neurodegeneration PRINCIPAL INVESTIGATOR : (2009) (0)
- Interaction of Synuclein and Inflammation in Dopaminergic Neurodegeneration (2010) (0)
- Dysfunction of mitochondrial oxidative phosphorylation in als rat model (2007) (0)
- Time course of the protective effect of transplantation on quinolinic acid-induced striatal lesion (1994) (0)
- Alpha‐tocopherol levels in Parkinsonian brains (1993) (0)
- Molsidomide provides neuroprotection against vincristine-induced peripheral neurotoxicity (2019) (0)
- Gordon, P. H. et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 66, 1117-1119 (2006) (0)
- Short Communication Pathogenic Lrrk2 substitutions and Amyotrophic lateral sclerosis (2007) (0)
- 3.205 NECDIN PREVENTS LOSS OF DOPAMINERGIC NEURONS IN ANIMAL MODELS OF PARKINSON'S DISEASE (2012) (0)
- Role of Inflammation in MPTP-Induced Dopaminergic Neuronal Death (2008) (0)
- Drug may put brakes on Parkinson's disease (2009) (0)
- NEURONAL PROTECTION AGAINST EXCITOTOXICITY. AUTHOR'S REPLY (1993) (0)
- O.020 Is there a pathogenic role for mitochondria in PD (2009) (0)
- Reply to: “Letter on Discussion of Gait Research” (2022) (0)
- AComputationalModel ofMotorNeuronDegeneration (2016) (0)
- Pre-Clinical Testing of New Hydroxybutyrate Analogues (2011) (0)
- DELAYED-ONSET DYSKINESIA. AUTHOR'S REPLY (1996) (0)
- 3.260 D-β-HYDROXYBUTYRATE IS NEUROPROTECTIVE IN MOUSE MODELS OF HUNTINGTON'S DISEASE (2012) (0)
- The Ubiquitination of PINK 1 Is Restricted to Its Mature 52-kDa Form Graphical Abstract Highlights (2017) (0)
- Cholecystokinin immunoreactivity and binding sites in hippocampal formation, striatum including related subcortical structures, brain stem and cerebellum of the human brain.: In: The Neuropeptide cholecystokinin (CCK). Anatomy and biochemistry receptors, pharmacology and physiology. pp 109-116 (1989) (0)
- The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study (2021) (0)
- Lackofefficacy ofphenytoin inthesyndrome ofinappropriate anti-diuretic hormone secretion ofneurological origin (1989) (0)
- Preface (2004) (0)
- NEURORESTORATION OF THE DOPAMINERGIC PATHWAY USING FOCUSED ULTRASOUND-MEDIATED PROTEIN AND GENE DELIVERY IN A PARKINSONIAN MODEL (2018) (0)
- Role of Inflammation in MPTP-Induced Dopaminergic Degeneration (2005) (0)
- Neuroprotective Small Molecules for the Treatment of Amyotrophic Lateral Sclerosis (2012) (0)
- Experimental Models of Motor Neuron Diseases (2005) (0)
- Astrocyte mediated toxicity leads to motor neuron death in Spinal Muscular Atrophy (S17.006) (2015) (0)
- Focused Ultrasound Enhanced Intranasal Delivery of Neurotrophic Factors Exhibit Neurorestorative Effects in Parkinson's Disease Mouse Model (2018) (0)
- The Interaction of Astrocytes and Motor Neurons in ALS (2009) (0)
- 3.7.3 ANIMAL MODELS OF PD (2012) (0)
- Toxicity of the specific antimuscarinic agent methoctramine and other non-specific anticholinergic drugs in human neuroblastoma cell lines in vitro. (1993) (0)
- New insights into the pathophysiology of dystonia (2011) (0)
- Lipid level alteration in human and cellular models of alpha synuclein mutations (2022) (0)
- Visualization of neuropeptides and neurotransmitters in the human brain. Applications to development and pathology.: Proceedings of the WENNER-GREN Conference on "Visualization of brain function" held at Stockholm, 1988. vol. 53, pp 31-40 (1989) (0)
- Functional Neural Transplantation. Edited by Stephen B. Dunnett and Anders Björklund. New York: Raven Press, 1994, 608 pp. Price: $145.00 (1996) (0)
- Clinical presentation and pharmacological therapy in cortico-basal ganglionic degeneration (1996) (0)
- Contents page + Editorial Board (2003) (0)
- A motif within the armadillo repeat of Parkinson’s-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway (2018) (0)
- Decision letter: Mitochondrial fusion is required for spermatogonial differentiation and meiosis (2019) (0)
- Reply (1996) (0)
- Program Project on the Pathogenesis and Treatment of Parkinson's Disease (2004) (0)
- Neuronal protection against excitotoxicity. (1993) (0)
- c-jun-N-Terminal Kinase (JNK) for the Treatment of Amyotrophic Lateral Sclerosis (2015) (0)
- [Pathogenesis and treatment of multiple sclerosis. Review and personal results]. (1988) (0)
- Role of Nitric Oxide in MPTP-Induced Dopaminergic Neuron Degeneration (2004) (0)
- Can a defect in bioenergetics be involved in the pathogenesis of Parkinson's disease after all? (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Serge E. Przedborski?
Serge E. Przedborski is affiliated with the following schools: